| Literature DB >> 34068374 |
Dominika Radomska1, Robert Czarnomysy1, Dominik Radomski1, Anna Bielawska2, Krzysztof Bielawski1.
Abstract
This review answers the question of why selenium is such an important trace element in the human diet. Daily dietary intake of selenium and its content in various food products is discussed in this paper, as well as the effects of its deficiency and excess in the body. Moreover, the biological activity of selenium, which it performs mainly through selenoproteins, is discussed. These specific proteins are responsible for thyroid hormone management, fertility, the aging process, and immunity, but their key role is to maintain a redox balance in cells. Furthermore, taking into account world news and the current SARS-CoV-2 virus pandemic, the impact of selenium on the course of COVID-19 is also discussed. Another worldwide problem is the number of new cancer cases and cancer-related mortality. Thus, the last part of the article discusses the impact of selenium on cancer risk based on clinical trials (including NPC and SELECT), systematic reviews, and meta-analyses. Additionally, this review discusses the possible mechanisms of selenium action that prevent cancer development.Entities:
Keywords: COVID-19; bioactive nutrients; cancer; cancer chemoprevention; essential nutrients; micronutrients; molecular mechanisms; nutrient sources; prevention; selenium
Year: 2021 PMID: 34068374 PMCID: PMC8153312 DOI: 10.3390/nu13051649
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Examples of some food products and their selenium content.
| Food | Typical Se Content (µg/g Fresh Weight) | References |
|---|---|---|
| Se-yeast | 3000 | [ |
| Broccoli (Se-enriched) | 62.3 | [ |
| Brazil nuts | 0.85–6.86 | [ |
| Shellfish | 0.36–1.33 | [ |
| Chicken | 0.57 | [ |
| Beef | 0.35–0.47 | [ |
| Lamb | 0.4 | [ |
| Salmon | 0.21–0.27 | [ |
| Eggs | 0.17 | [ |
| Milk products | 0.1–0.55 | [ |
Recommended daily intakes of selenium for individuals in different age groups and genders. The Adequate Intake (AI) is equivalent to the mean selenium intake of healthy, breastfed infants from birth to 12 months of age, as established by the Food and Nutrition Board (FNB) [13].
| Age Group | Male (µg/d) | Female (µg/d) | Pregnancy (µg/d) | Lactation (µg/d) |
|---|---|---|---|---|
| Birth to 6 mths | 15 * | 15 * | ||
| 7 to 12 mths | 20 * | 20 * | ||
| 9 to 13 yrs | 40 | 40 | ||
| 14 to 18 yrs | 55 | 55 | 60 | 70 |
| 19 to 30 yrs | 55 | 55 | 60 | 70 |
| 31 to 50 yrs | 55 | 55 | 60 | 70 |
| 50 to 71 yrs | 55 | 55 | ||
| Above 71 yrs | 55 | 55 |
* Adequate Intake (AI).
Figure 1The range of normal (optimal) plasma selenium levels. Values above and below this range indicate selenium toxicity or deficiency, respectively.
Figure 2Selenoprotein families and their localization in the human body [2,82,85,86]. ER—endoplasmic reticulum, CNS—central nervous system.
Figure 3Selenoproteins of the glutathione peroxidases (GPx) family and their functions [85,87,88,89].
Figure 4Selenoproteins of the thioredoxin reductases (TrxR) family and their functions [102,103,104,105].
Figure 5Selenoproteins of the iodothyronine deiodinases (DIO) family and their functions [114,115,117,118,119].
Figure 6Other selenoproteins and their functions [8,55,82,86,128,129,130,131,132,133].
Recent and current clinical trials on selenium chemoprevention in breast, colorectal, lung, and prostate cancer. This table was compiled from the information available at https://www.clinicaltrials.gov/ (accessed on 25 October 2020).
| NCT Identification Number | Study Title | Clinical Trial Status | Type of Cancer | Study Design | References |
|---|---|---|---|---|---|
| NCT00555386 | Soy, selenium, and breast cancer risk | Not applicable b | Breast Cancer | Randomized, double-blind (participant, investigator), placebo-controlled, parallel assignment | [ |
| NCT04014283 | Prevention of female cancers by optimization of selenium levels in the organism (SELINA) | Not applicable c,d | Breast Cancer | Randomized, single-blind (investigator), placebo-controlled, parallel assignment | [ |
| NCT01611038 | Chemoprevention of breast and prostate cancers in shift workers by dietary methylselenocysteine: effects on circadian rhythm and estrogen receptor-B cycling | Not applicable b | Breast and Prostate Cancer | Randomized, triple-blind (participant, investigator, outcomes assessor), placebo-controlled, parallel assignment | [ |
| NCT01211561 | Colon cancer prevention using selenium | Unknown b,* | Colorectal Cancer | Randomized, double-blind (participant, investigator), placebo-controlled, single group assignment | [ |
| NCT00706121 | S0000D: Effect of vitamin E and/or selenium on colorectal polyps in men enrolled on SELECT trial SWOG-S0000 (ACP) | Phase 3 | Colorectal Cancer | Randomized, quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled, parallel assignment | [ |
| NCT01437826 | Antioxidant supplement and reduction of metachronous adenomas of the large bowel: a double blind randomized trial | Phase 3 | Colorectal Cancer | Randomized, double-blind (participant, investigator), placebo-controlled, parallel assignment | [ |
| NCT00008385 | Selenium in preventing tumor growth in patients with previously resected stage I non-small cell lung cancer | Phase 3 | Lung Cancer | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled, parallel assignment | [ |
| NCT00978718 | Selenium in preventing prostate cancer | Phase 3 | Prostate Cancer | Randomized, double-blind, placebo-controlled | [ |
| NCT00446901 | Selenium and prostate cancer: clinical trial on availability to prostate tissue and effects on gene expression (SePros) | Not applicable b | Prostate Cancer | Randomized, quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled, parallel assignment | [ |
| NCT00006392 | S0000: Selenium and vitamin E in preventing prostate cancer (SELECT) | Phase 3 | Prostate, Cancer | Randomized, quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled, factorial assignment | [ |
| NCT00030901 | S9917: Selenium in preventing cancer in patients with neoplasia of the prostate | Phase 3 | Prostate Cancer | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled, parallel assignment | [ |
| NCT00064194 | Vitamin E, selenium, and soy protein in preventing cancer in patients with high-grade prostate neoplasia | Phase 3 | Prostate Cancer | Randomized, triple-blind (participant, care provider, investigator), placebo-controlled | [ |
| NCT01497431 | Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants | Phase 1 | Prostate Cancer | Randomized, double-blind (participant, investigator), placebo-controlled, parallel assignment | [ |
a study started before the SELECT trial. b study started during the SELECT trial. c study started after results of the SELECT trial. d recruitment to the target population is ongoing. + results of the study are available on ClinicalTrials.gov. * no verification of status >2 years despite completion date has passed.
Figure 7Possible mechanisms of cancer chemoprevention by selenium.